[go: up one dir, main page]

TR200001959T2 - Arsenik bileşikleri kullanılarak primer ve metastatik neoplastik hastalıkların tedavisi için bileşimler ve yöntemler. - Google Patents

Arsenik bileşikleri kullanılarak primer ve metastatik neoplastik hastalıkların tedavisi için bileşimler ve yöntemler.

Info

Publication number
TR200001959T2
TR200001959T2 TR2000/01959T TR200001959T TR200001959T2 TR 200001959 T2 TR200001959 T2 TR 200001959T2 TR 2000/01959 T TR2000/01959 T TR 2000/01959T TR 200001959 T TR200001959 T TR 200001959T TR 200001959 T2 TR200001959 T2 TR 200001959T2
Authority
TR
Turkey
Prior art keywords
compositions
primary
treatment
methods
neoplastic diseases
Prior art date
Application number
TR2000/01959T
Other languages
English (en)
Inventor
M: Ellison Ralph
H. Mermelstein Fred
Original Assignee
Polarx Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polarx Biopharmaceuticals, Inc. filed Critical Polarx Biopharmaceuticals, Inc.
Publication of TR200001959T2 publication Critical patent/TR200001959T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Bulus, çesitli neoplastik hastaliklarin tedavi edilmesi için asenik bilesiklerinin kullanimina iliskindir. Bundan baska, arsenik bilesikleri metastatik neoplastik hastaliklarin tedavi edilmesi için kullanilabilmektedir.
TR2000/01959T 1997-10-15 1998-10-15 Arsenik bileşikleri kullanılarak primer ve metastatik neoplastik hastalıkların tedavisi için bileşimler ve yöntemler. TR200001959T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6237597P 1997-10-15 1997-10-15

Publications (1)

Publication Number Publication Date
TR200001959T2 true TR200001959T2 (tr) 2000-11-21

Family

ID=22042073

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01959T TR200001959T2 (tr) 1997-10-15 1998-10-15 Arsenik bileşikleri kullanılarak primer ve metastatik neoplastik hastalıkların tedavisi için bileşimler ve yöntemler.

Country Status (20)

Country Link
US (9) US6875451B2 (tr)
EP (9) EP1621077B1 (tr)
JP (1) JP2001519366A (tr)
KR (1) KR20010015755A (tr)
CN (1) CN1282218A (tr)
AT (4) ATE407683T1 (tr)
AU (1) AU751932B2 (tr)
BR (1) BR9813085A (tr)
CA (1) CA2307208A1 (tr)
CY (4) CY1108363T1 (tr)
DE (4) DE69840006D1 (tr)
DK (4) DK1621077T3 (tr)
ES (4) ES2358624T3 (tr)
IL (1) IL135620A0 (tr)
NO (1) NO20001977L (tr)
NZ (1) NZ503973A (tr)
PL (1) PL339909A1 (tr)
PT (4) PT1621077E (tr)
TR (1) TR200001959T2 (tr)
WO (1) WO1999018798A1 (tr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
AUPQ296799A0 (en) 1999-09-20 1999-10-14 Unisearch Limited A cell-membrane impermeable trivalent organoarsenical derivative and use thereof
AUPR379801A0 (en) 2001-03-19 2001-04-12 Unisearch Limited Use of a substantially cell membrane impermeable compound for treating arthritis
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
DE10196619D2 (en) * 2001-07-05 2004-05-06 Hans-Werner Luedke Nahrungsergänzungsprodukt oder arzneimittel gegen bestimmte mangelzustände und hirnfunktionsstörungen
AUPR874601A0 (en) * 2001-11-08 2001-11-29 Unisearch Limited Selective targeting of apoptotic cells
KR20030058019A (ko) * 2001-12-29 2003-07-07 한국원자력연구소 삼산화비소(Ａｓ₂Ｏ₃)를 유효 성분으로 포함하는 방사선치료증진제
WO2003057012A2 (en) * 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
CA2481602C (en) * 2002-04-10 2011-06-21 Korea Microbiological Laboratories, Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
FR2838965B1 (fr) 2002-04-26 2004-06-25 Centre Nat Rech Scient Therapie par l'arsenic du syndrome autoimmunlymphoproliferatif de type apls chez la souris comme chez l'homme
US8394422B2 (en) * 2002-04-26 2013-03-12 Centre National De La Recherche Scientifique (Cnrs) Arsenic therapy for autoimmune and/or inflammatory diseases in mice and humans
KR100492940B1 (ko) * 2002-05-27 2005-06-02 김종배 항종양활성 증진용 조성물
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
ES2330519T3 (es) 2002-11-07 2009-12-11 Newsouth Innovations Pty Limited Inducion de la transicion de permeabilidad mitocondrial.
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
WO2005062810A2 (en) * 2003-12-18 2005-07-14 Mediscovery, Llc Treatment of primary and metastatic neoplastic diseases with tetraarsenic decaoxide
KR20060125916A (ko) * 2004-03-01 2006-12-06 펩팀문, 인코포레이티드 자가면역 질병을 치료하기 위한 방법 및 조성물
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US20050208149A1 (en) * 2004-03-18 2005-09-22 Tty Biopharm Limited Company Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
WO2006002082A2 (en) 2004-06-16 2006-01-05 Jack Arbiser Carbazole formulations for the treatment of psoriasis and angiogenesis
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
EP1789107B1 (en) * 2004-08-30 2009-05-27 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
EP1865972B1 (en) * 2005-03-23 2013-11-06 CHS Pharma, Inc. Treatment or prevention of cancer and precancerous disorders
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
EP2394702B1 (en) 2005-07-29 2014-12-31 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US8246983B2 (en) * 2005-09-02 2012-08-21 Northwestern University Encapsulated arsenic drugs
US8784899B2 (en) * 2005-10-04 2014-07-22 Samuel Waxman Cancer Research Foundation Compositions and methods for cancer treatment
US20080233207A1 (en) * 2006-01-04 2008-09-25 Sheptovitsky Yelena G Injectable and Infusable Mercury Compositions and Methods for Treating Cancer
ITMI20060480A1 (it) * 2006-03-16 2007-09-17 Solvay Solexis Spa Usom di perfluoropolimeri nella dtermibnazione della costante di legame recettore-ligando
US20090018142A9 (en) * 2006-05-02 2009-01-15 Zhengping Zhuang Use of phosphatases to treat tumors overexpressing N-CoR
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
JP5301449B2 (ja) 2006-11-01 2013-09-25 ニューサウス イノベイションズ ピーティーワイ リミテッド 有機アルセノキシド化合物およびその使用
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
AU2008214299B2 (en) * 2007-02-06 2014-01-09 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
US20090035292A1 (en) * 2007-08-03 2009-02-05 Kovach John S Use of phosphatases to treat neuroblastomas and medulloblastomas
MX2010003417A (es) * 2007-10-01 2010-09-10 Lixte Biotechnology Inc Inhibidores de histona desacetilasa.
CA2704395A1 (en) * 2007-11-02 2009-05-14 Ziopharm Oncology, Inc. Combination therapy with organic arsenicals
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
EP2318005B1 (en) 2008-08-01 2017-11-01 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
US8227473B2 (en) 2008-08-01 2012-07-24 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2010014141A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
PT2321012T (pt) 2008-08-20 2019-01-11 Solasia Pharma K K Compostos organoarsénicos e métodos para o tratamento de cancro
KR101100786B1 (ko) * 2008-12-16 2011-12-29 (주)천지산 암에 대한 방사선 치료 증진용 조성물
WO2011031890A2 (en) * 2009-09-10 2011-03-17 Kominox Usa, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
JP2013505242A (ja) * 2009-09-18 2013-02-14 コミノックス・インコーポレイテッド 脳腫瘍を治療するための方法
US20120015023A1 (en) * 2010-04-15 2012-01-19 Antimisiaris Sophia G Treatment of tumors prostate with arsonoliposomes
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
US20160015743A1 (en) * 2013-03-15 2016-01-21 Rush University Medical Center Methods for treating cancer
EP2983661B1 (en) 2013-04-09 2024-05-29 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
FR3004949B1 (fr) * 2013-04-26 2016-02-05 Centre Nat Rech Scient Traitement de maladies autoimmunes et inflammatoires par les composes de l'arsenic as203 et/ou as205 administres par voie locale
US9700580B1 (en) 2016-06-14 2017-07-11 Marguerite Harning Method for cancer treatment
MX384297B (es) 2016-12-01 2025-03-14 Eupharma Pty Ltd Composiciones de arsénico.
WO2018107004A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
KR101844050B1 (ko) 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
WO2018209343A1 (en) * 2017-05-12 2018-11-15 Rajur Sharanappa Basappa Novel methods, compounds, and compositions: small molecule anticancer agents
WO2019234112A1 (en) 2018-06-05 2019-12-12 Katholieke Universiteit Leuven Combination treatment of arsenic oxide and antiandrogens
CN112675197A (zh) * 2021-01-22 2021-04-20 中山大学孙逸仙纪念医院 一种用于儿童Hedgehog信号通路驱动肿瘤的药物组合物
US20240139108A1 (en) * 2021-02-26 2024-05-02 Intas Pharmaceuticals Ltd. Oral pharmaceutical composition of arsenic trioxide
CN114028425A (zh) * 2021-09-24 2022-02-11 上海交通大学医学院附属新华医院 硫化砷及其与放疗联合在治疗横纹肌肉瘤上的应用
CN115634287A (zh) * 2022-09-30 2023-01-24 苏州系统医学研究所 一种基于砷化合物的肿瘤疫苗及其制备方法和应用
DE102023114756B4 (de) 2023-06-06 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit Kühlstruktur sowie Fahrzeug mit der Bremsvorrichtung
DE102023123187B4 (de) 2023-08-29 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung für ein Fahrzeug, Antriebsanordnung mit der Bremsvorrichtung sowie Fahrzeug
DE102023123189B4 (de) 2023-08-29 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit einer Synchroneinrichtung für ein Fahrzeug sowie Fahrzeug mit der Bremsvorrichtung
DE102023123190B4 (de) 2023-08-29 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit einer Mehrzahl von Bremsscheiben sowie Fahrzeug mit der Bremsvorrichtung
DE102023123673B4 (de) 2023-09-04 2025-03-13 Schaeffler Technologies AG & Co. KG Bremsvorrichtung mit einer Magnetkupplungseinrichtung für ein Fahrzeug sowie Fahrzeug mit der Bremsvorrichtung

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132275A (en) 1872-10-15 Improvement in medical compounds
US232807A (en) 1880-10-05 Herbert e
US3700498A (en) 1970-12-10 1972-10-24 Ibm Process for making electrophotographic plates
JPS5188620A (en) 1975-01-31 1976-08-03 Jintainokenkonoiji kotonigannitaishitekonoojusuru noshukuionekinoseizoho
DE3003635C2 (de) 1980-02-01 1985-07-11 Klöckner-Humboldt-Deutz AG, 5000 Köln Verfahren und Vorrichtung zur Entarsenierung arsenhaltiger Materialien
US4599305A (en) * 1984-07-16 1986-07-08 The Regents Of The University Of California Method and composition for detection of human chronic myelogenous leukemia
NL8502929A (nl) * 1985-10-25 1987-05-18 Tno Groep viii-overgangsmetaal-complexen, werkwijze voor het bereiden daarvan, werkwijze voor het bereiden van een geneesmiddel met toepassing van een dergelijke groep viii-overgangsmetaal-complex voor de behandeling van kanker, alsmede aldus verkregen gevormd geneesmiddel.
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
CN1061908A (zh) 1991-12-21 1992-06-17 江西省妇产医院 一种治癌药物的制造方法
CN1060935C (zh) 1992-05-31 2001-01-24 丛繁滋 用于癌病灶直接给药的砷制剂的制备方法
CN1044777C (zh) 1992-07-06 1999-08-25 杨世泽 癌痛止痛膏的配制方法
ATE225167T1 (de) 1992-07-24 2002-10-15 Univ Johns Hopkins Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs
FR2699820B3 (fr) * 1992-12-24 1995-03-10 Eric Pichot Traitement homéopathique préventif des dysmytoses (cancer, leucémie) et malformations ou mutations génétiques.
DE4317331A1 (de) * 1993-05-25 1994-12-01 Reischle Karl Georg Behandlung von Schädigungen des Immunsystems
ITTO930510A1 (it) 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
WO1995022336A1 (en) 1994-02-18 1995-08-24 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1119113A (zh) 1994-09-22 1996-03-27 衣永德 复方癌复康胶囊及制备方法
CN1122700A (zh) 1994-11-08 1996-05-22 付知中 一种治疗乳腺疾病、肿瘤疮毒的散剂及其制备方法
LV11667B (en) * 1995-08-14 1997-06-20 Tamara Vorobieva Remedy for renewal of disordered function of immunomodulation and cell tissue reproduction adjustors
CN1044559C (zh) 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
KR19990064070A (ko) * 1995-10-06 1999-07-26 피터 이. 외팅거 체강내면의 엑스-선 조사장치
CN1058620C (zh) 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
CN1052648C (zh) 1995-12-03 2000-05-24 唐书生 癌瘤消肿止痛膏
IL136051A0 (en) 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
CA2499738A1 (en) * 2002-09-24 2004-04-08 Novartis Ag Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
US20050196464A1 (en) * 2004-03-03 2005-09-08 Tty Biopharm Company Limited Method and pharmaceutical composition for treatment of skin neoplasm

Also Published As

Publication number Publication date
US6875451B2 (en) 2005-04-05
EP1378240A3 (en) 2004-01-14
CY1108363T1 (el) 2014-02-12
EP1374875A3 (en) 2004-01-07
JP2001519366A (ja) 2001-10-23
ES2313201T3 (es) 2009-03-01
CY1110057T1 (el) 2015-01-14
DE69839682D1 (de) 2008-08-14
IL135620A0 (en) 2001-05-20
US7179493B2 (en) 2007-02-20
DK1391206T3 (da) 2008-09-01
EP1391206B1 (en) 2008-07-02
PT2018858E (pt) 2011-03-24
US20050100611A1 (en) 2005-05-12
US20040197421A1 (en) 2004-10-07
HK1085886A1 (en) 2006-09-08
PT1378240E (pt) 2008-11-14
DK2018858T3 (da) 2013-01-07
US7132116B2 (en) 2006-11-07
NO20001977D0 (no) 2000-04-14
CN1282218A (zh) 2001-01-31
EP1022951A1 (en) 2000-08-02
EP1466607A1 (en) 2004-10-13
EP1391206A1 (en) 2004-02-25
DK1378240T3 (da) 2008-12-08
KR20010015755A (ko) 2001-02-26
EP1374875A2 (en) 2004-01-02
ATE409043T1 (de) 2008-10-15
EP1378241A1 (en) 2004-01-07
HK1061198A1 (en) 2004-09-10
NO20001977L (no) 2000-06-13
NZ503973A (en) 2001-09-28
CY1111379T1 (el) 2015-08-05
EP1378240A2 (en) 2004-01-07
EP1022951A4 (en) 2002-06-19
BR9813085A (pt) 2000-08-22
PL339909A1 (en) 2001-01-15
CA2307208A1 (en) 1999-04-22
CY1110055T1 (el) 2015-01-14
ATE493979T1 (de) 2011-01-15
ES2309258T3 (es) 2008-12-16
ATE407683T1 (de) 2008-09-15
US20040096518A1 (en) 2004-05-20
EP2018858B1 (en) 2011-01-05
US20020183385A1 (en) 2002-12-05
EP2018858A1 (en) 2009-01-28
PT1621077E (pt) 2008-11-04
DE69842094D1 (de) 2011-02-17
EP1621077B1 (en) 2008-09-24
US7163703B2 (en) 2007-01-16
AU751932B2 (en) 2002-08-29
ATE399560T1 (de) 2008-07-15
DE69840057D1 (de) 2008-11-06
HK1061199A1 (en) 2004-09-10
PT1391206E (pt) 2008-08-13
DK1621077T3 (da) 2009-01-26
US20040047916A1 (en) 2004-03-11
US20050191367A1 (en) 2005-09-01
EP1621077A1 (en) 2006-02-01
ES2358624T3 (es) 2011-05-12
ES2312701T3 (es) 2009-03-01
EP1378240B1 (en) 2008-09-10
EP1419778A1 (en) 2004-05-19
DE69840006D1 (de) 2008-10-23
AU1089399A (en) 1999-05-03
WO1999018798A1 (en) 1999-04-22
US20040161475A1 (en) 2004-08-19
US20040197420A1 (en) 2004-10-07
US7205001B2 (en) 2007-04-17
US20040115283A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
TR200001959T2 (tr) Arsenik bileşikleri kullanılarak primer ve metastatik neoplastik hastalıkların tedavisi için bileşimler ve yöntemler.
EP0284362A3 (en) Molecular markers
DE60040981D1 (de) BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN
AR033157A1 (es) Uso de proteina alfa de activacion de los fibroblastos ("fapaalfa")bibh1 en el tratamiento del cancer
DE60003583D1 (de) Arylaminderivate und ihre verwendung als antitelomerasemittel
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
DE69109283D1 (de) Verfahren zur sensibilisierung von tumorzellen.
BR0215689A (pt) Composição farmacêutica compreendendo arsênico para o tratamento de malignidade
ATE64531T1 (de) Tumortherapeutikum und verfahren zu seiner herstellung.
IL64332A0 (en) Compounds of dichlorodiethylamino-phenylalanine with anti-cancer tumor activity
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
ATE306255T1 (de) 19-nor-vitamin d3 derivate mit calciumspiegel erhöhender wirkung
PT1427420E (pt) Utilizacao de uma combinacao compreendendo 4- piridilmetilftalazinas para o tratamento do cancro
DK1140147T3 (da) hCG-terapi til behandling af metastatisk brystcancer
ID16885A (id) Stimulasi mekanisme pertahanan pejamu melawan tumor.
DE59106972D1 (de) Pharmazeutisch brauchbare Naphthalin- und Anthracenderivate.
EP0786523A3 (en) Protein kinase and method of using
CA2206567A1 (en) Method and composition for reducing tumor development with a combination of a taxane compound and a tellurium and/or selenium compound